Poly(ADP-Ribosylation): Beneficial effects of its inhibition

Current Enzyme Inhibition

Volumn 5, Issue 2, 2009, Pages 99-109

  Giansanti, V ^a   Dona F ^a   Scovassi, A I ^a  

^a CNR   (Italy)

Author keywords

Cancer; Inflammation; Neurodegenerative diseases; PARG inhibitors; PARP inhibitors; Poly(ADP ribosylation); Telomeres

Indexed keywords

(4 AMINO 1,8 NAPHTHALIMIDE); 2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 2 AMINOBENZAMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; AG 14361; BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; GPI 15427; INO 1001; IRINOTECAN; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 4; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PEPLEOMYCIN; POLY(ADENOSINE DIPHOSPHATE RIBOSE); POLY(ADENOSINE DIPHOSPHATE RIBOSE)GLYCOHYDROLASE; REACTIVE OXYGEN METABOLITE; TANKYRASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANTINEOPLASTIC ACTIVITY; ASCITES TUMOR; CELL PROTECTION; CHEMOSENSITIZATION; COLON CARCINOMA; DIABETES MELLITUS; DNA DAMAGE; DNA REPAIR; DRUG PENETRATION; DRUG POTENTIATION; ENZYME ACTIVATION; GLIOMA; HEART DISEASE; HUMAN; INFLAMMATION; MELANOMA; NEUROLOGIC DISEASE; NONHUMAN; PROTEIN PROTEIN INTERACTION; RADIOSENSITIZATION; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 70350037550     PISSN: 15734080     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340809788680484     Document Type: Review

References (130)

1. Schreiber, V.; Dantzer, F.; Amé, J. C.; de Murcia, G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol., 2006, 7, 517-528.
2. Hassa, P.O.; Haenni, S.S.; Elser, M.; Hottiger, M.O. Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? Microbiol. Mol. Biol. Rev., 2006, 70, 789-829.
3. Amé, J.C.; Spenlehauer, C.; de Murcia, G. The PARP superfamily. BioEssays, 2004, 26, 882-893.
4. Hassa, P.O.; Hottiger, M.O. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front. Biosci., 2008, 13, 3046-3082.
5. Frouin, I.; Scovassi, A.I. Poly(ADP-ribosylation) regulates DNA replication and repair. In DNA replication, repair and recombination at the crossroad between genome integrity and genomic instability: a biochemical perspective. Maga, G. Ed; Research Signpost, Kerala, India, 2008, 115-130.
6. Hakme, A.; Wong, H.K.; Dantzer, F.; Schreiber, V. The expanding field of poly(ADP-ribosyl)ation reactions. EMBO Rep., 2008, 9, 1094-1100.
7. Bürkle, A. DNA repair and PARP in aging. Free Radic. Res., 2006, 40, 1295-1302.
8. Jeggo, P.A. DNA repair: PARP - another guardian angel? Curr. Biol., 1998, 8, R49-51.
9. Tong, W.M.; Cortes, U.; Wang, Z.Q. Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. Biochim. Biophys. Acta, 2001, 1552, 27-37.
10. Woodhouse, B.C.; Dianov, G.L. Poly ADP-ribose polymerase-1: an international molecule of mystery. DNA Repair, 2008, 7, 1077-1086.
11. Till, S.; Diamantara, K.; Ladurner, A.G. PARP: a transferase by any other name. Nat. Struct. Mol. Biol., 2008, 15, 1243-1244.
12. Yélamos, J.; Schreiber, V.; Dantzer, F. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol. Med., 2008, 14, 169-178.
13. Berger, W.; Steiner, E.; Grusch, M.; Elbling, L.; Micksche, M. Vaults and the major vault protein: Novel roles in signal pathway regulation and immunity. Cell Mol. Life Sci., 2008, in press.
14. Liu, Y.; Snow, B.E.; Kickhoefer, V.A.; Erdmann, N.; Zhou, W.; Wakeham, A.; Gomez, M.; Rome, L.H.; Harrington, L. Vault poly(ADP-ribose) polymerase is associated with mammalian telomerase and is dispensable for telomerase function and vault structure in vivo. Mol. Cell Biol., 2004, 24, 5314-5323.
15. Donà, F.; Mondello, C.; Scovassi, A.I. Poly(ADP-ribosylation) at telomers. Trends Cell Mol. Biol., 2007, 2, 77-88.
16. Bonicalzi, M.E.; Haince, J.F.; Droit, A.; Poirier, G. G. Regulation of poly(ADP-ribose) metabolism by poly(ADP-ribose) glycohydrolase: where and when? Cell Mol. Life Sci., 2005, 62, 739-750.
17. Miwa, M.; Sugimura, T. Splitting of the ribose-ribose linkage of poly(adenosine diphosphate-robose) by a calf thymus extract. J. Biol. Chem., 1971, 246, 6362-6364.
18. Koh, D.W.; Dawson, V.L.; Dawson, T.M. The road to survival goes through PARG. Cell Cycle, 2005, 4, 397-399.
19. Gagné, J.P.; Hendzel, M.J.; Droit, A.; Poirier, G.G. The expanding role of poly(ADP-ribose) metabolism: current challenges and new perspectives. Curr. Opin. Cell Biol., 2006, 18, 145-151.
20. Niere, M.; Kernstock, S.; Koch-Nolte, F.; Ziegler, M. Functional localization of two poly(ADP-ribose)-degrading enzymes to the mitochondrial matrix. Mol. Cell Biol., 2008, 28, 814-824.
21. Scovassi, A.I. Mitochondrial poly(ADP-ribosylation): from old data to new perspectives. FASEB J., 2004, 18, 1487-1488.
22. Clark, J.B.; Ferris, G.M.; Pinder, S. Inhibition of nuclear NAD nucleosidase and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5′-methyl nicotinamide. Biochim. Biophys. Acta, 1971, 238, 82-85.
23. Clark, J.B.; Pinder, S. Control of the steady-state concentrations of the nicotinamide nucleotides in rat liver. Biochem. J., 1969, 114, 321-330.
24. Colyer, R.A.; Burdette, K.E.; Kidwell, W.R. Poly ADP-ribose synthesis and DNA replication in synchronized mouse L-cells. Biochem. Biophys. Res. Commun., 1973, 53, 960-966.
25. Purnell, M.R.; Whish, W. J. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem. J., 1980, 185, 775-777.
26. Shall, S. Proceedings: Experimental manipulation of the specific activity of poly(ADP-ribose) polymerase. J. Biochem., 1975, 77, 2.
27. Durkacz, B.W.; Omidiji, O.; Gray, D.A.; Shall, S. (ADP-ribose)n participates in DNA excision repair. Nature, 1980, 283, 593-596.
28. Shall, S.; de Murcia, G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat. Res., 2000, 460, 1-15.
29. Dantzer, F.; Schreiber, V.; Niedergang, C.; Trucco, C.; Flatter, E.; De La Rubia, G.; Oliver, J.; Rolli, V.; Ménissier-de Murcia, J.; de Murcia, G. Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie, 1999, 81, 69-75.
30. Lavrik, O.I.; Prasad, R.; Sobol, R.W.; Horton, J.K.; Ackerman, E.J.; Wilson, S.H. Photoaffinity labeling of mouse fibroblast enzymes by a base excision repair intermediate. Evidence for the role of poly(ADP-ribose) polymerase-1 in DNA repair. J. Biol. Chem., 2001, 276, 25541-25548.
31. Jagtap, P.; Szabo, C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov., 2005, 4, 421-440.
32. Sestili, P.; Spadoni, G.; Balsamini, C.; Scovassi, I.; Cattabeni, F.; Duranti, E.; Cantoni, O.; Higgins, D.; Thomson, C. Structural requirements for inhibitors of poly(ADP-ribose) polymerase. J. Cancer Res. Clin. Oncol., 1990, 116, 615-622.
33. Ruf, A.; Ménissier de Murcia, J.; de Murcia, G.; Schulz, G.E. Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken. Proc. Natl. Acad. Sci. USA, 1996, 93, 7481-7485.
34. Ruf, A.; de Murcia, G.; Schulz, G.E. Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry, 1998, 37, 3893-3900.
35. Oliver, A.W.; Amé, J.C.; Roe, S.M.; Good, V.; de Murcia, G.; Pearl, L.H. Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2. Nucleic Acids Res., 2004, 32, 456-464.
36. Banasik, M.; Komura, H.; Shimoyama, M.; Ueda, K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl) transferase. J. Biol. Chem., 1992, 267, 1569-1575.
37. Wayman, N.; McDonald, M.C.; Thompson, A.S.; Threadgill, M.D.; Thiemermann, C. 5-aminoisoquinolinone, a potent inhibitor of poly (adenosine 5′-diphosphate ribose) polymerase, reduces myocardial infarct size. Eur. J. Pharmacol., 2001, 430, 93-100.
38. Zingarelli, B.; O'Connor, M.; Hake, P.W. Inhibitors of poly (ADP-ribose) polymerase modulate signal transduction pathways in colitis. Eur. J. Pharmacol., 2003, 469, 183-194.
39. Skalitzky, D.J.; Marakovits, J.T.; Maegley, K.A.; Ekker, A.; Yu, X.H.; Hostomsky, Z.; Webber, S.E.; Eastman, B.W.; Almassy, R.; Li, J.; Curtin, N.J.; Newell, D.R.; Calvert, A.H.; Griffin, R.J.; Golding, B.T. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J. Med. Chem., 2003, 46, 210-213.
40. Tikhe, J.G.; Webber, S.E.; Hostomsky, Z.; Maegley, K.A.; Ekkers, A.; Li, J.; Yu, X.H.; Almassy, R.J.; Kumpf, R.A.; Boritzki, T.J.; Zhang, C.; Calabrese, C.R.; Curtin, N.J.; Kyle, S.; Thomas, H.D.; Wang, L.Z.; Calvert, A.H.; Golding, B.T.; Griffin, R.J.; Newell, D.R. Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. J. Med. Chem., 2004, 47, 5467-5481.
41. Ferraris, D.; Ficco, R.P.; Pahutski, T.; Lautar, S.; Huang, S.; Zhang, J.; Kalish, V. Design and synthesis of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evaluation of 1,3,4,5-tetrahydro-benzo[c][1,6]- and [c][1,7]-naphthyridin-6-ones. Bioorg. Med. Chem. Lett., 2003, 13, 2513-2518.
42. Kinoshita, T.; Nakanishi, I.; Warizaya, M.; Iwashita, A.; Kido, Y.; Hattori, K.; Fujii, T. Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase. FEBS Lett., 2004, 556, 43-46.
43. Hattori, K.; Kido, Y.; Yamamoto, H.; Ishida, J.; Kamijo, K.; Murano, K.; Ohkubo, M.; Kinoshita, T.; Iwashita, A.; Mihara, K.; Yamazaki, S.; Matsuoka, N.; Teramura, Y.; Miyake, H. Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase. J. Med. Chem., 2004, 47, 4151-4154.
44. Ishida, J.; Yamamoto, H.; Kido, Y.; Kamijo, K.; Murano, K.; Miyake, H.; Ohkubo, M.; Kinoshita, T.; Warizaya, M.; Iwashita, A.; Mihara, K.; Matsuoka, N.; Hattori, K. Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling. Bioorg. Med. Chem., 2006, 14, 1378-1390.
45. Jagtap, P.; Soriano, F.G.; Virag, L.; Liaudet, L.; Mabley, J.; Szabo, E.; Hasko, G.; Marton, A.; Lorigados, C.B.; Gallyas, F., Jr.; Sumegi, B.; Hoyt, D.G.; Baloglu, E.; VanDuzer, J.; Salzman, A.L.; Southan, G.J.; Szabo, C. Novel phenanthridinone inhibitors of poly (adenosine 5′-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit. Care Med., 2002, 30, 1071-1082.
46. Jagtap, P.G.; Baloglu, E.; Southan, G.J.; Mabley, J.G.; Li, H.; Zhou, J.; van Duzer, J.; Salzman, A.L.; Szabo, C. Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J. Med. Chem., 2005, 48, 5100-5103.
47. Tao, M.; Park, C.H.; Bihovsky, R.; Wells, G.J.; Husten, J.; Ator, M.A.; Hudkins, R.L. Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 938-942.
48. Haince, J.F.; Rouleau, M.; Hendzel, M.J.; Masson, J.Y.; Poirier, G.G. Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy. Trends Mol. Med., 2005, 11, 456-463.
49. Sheridan, C. Genentech raises stakes on PARP inhibitors. Nat. Biotechnol., 2006, 24, 1179-1180.
50. Cuzzocrea, S. Shock, inflammation and PARP. Pharmacol. Res., 2005, 52, 72-82.
51. Virag, L.; Szabo, C. Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death. FASEB J., 2001, 15, 99-107.
52. Genovese, T.; Mazzon, E.; Muia, C.; Patel, N.S.; Threadgill, M.D.; Bramanti, P.; De Sarro, A.; Thiemermann, C.; Cuzzocrea, S. Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma. J. Pharmacol. Exp. Ther., 2005, 312, 449-457.
53. Beneke, S.; Diefenbach, J.; Bürkle, A. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int. J. Cancer, 2004, 111, 813-818.
54. Chiarugi, A. Poly(ADP-ribosyl)ation and stroke. Pharmacol. Res., 2005, 52, 15-24.
55. Graziani, G.; Szabo, C. Clinical perspectives of PARP inhibitors. Pharmacol. Res., 2005, 52, 109-118.
56. Ilnytska, O.; Lyzogubov, V.V.; Stevens, M.J.; Drel, V.R.; Mashtalir, N.; Pacher, P.; Yorek, M.A.; Obrosova, I.G. Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. Diabetes, 2006, 55, 1686-1694.
57. Kauppinen, T.M.; Swanson, R.A. The role of poly(ADP-ribose) polymerase-1 in CNS disease. Neuroscience, 2007, 145, 1267-1272.
58. Pacher, P.; Szabo, C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc. Drug Rev., 2007, 25, 235-260.
59. Szabo, C. Cardioprotective effects of poly(ADP-ribose) polymerase inhibition. Pharmacol. Res., 2005, 52, 34-43.
60. Virag, L. Poly(ADP-ribosyl)ation in asthma and other lung diseases. Pharmacol. Res., 2005, 52, 83-92.
61. Genovese, T.; Cuzzocrea, S. Role of free radicals and poly(ADP-ribose) polymerase-1 in the development of spinal cord injury: new potential therapeutic targets. Curr. Med. Chem., 2008, 15, 477-487.
62. Sharma, S.S.; Kumar, A.; Kaundal, R.K. Protective effects of 4-amino1,8-napthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy. Life Sci., 2008, 82, 570-576.
63. Obrosova, I.G.; Xu, W.; Lyzogubov, V.V.; Ilnytska, O.; Mashtalir, N.; Vareniuk, I.; Pavlov, I.A.; Zhang, J.; Slusher, B.; Drel, V.R. PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. Free Radic. Biol. Med., 2008, 44, 972-981.
64. Chen, H.; Jia, W.; Xu, X.; Fan, Y.; Zhu, D.; Wu, H.; Xie, Z.; Zheng, Z. Upregulation of PEDF expression by PARP inhibition contributes to the decrease in hyperglycemia-induced apoptosis in HUVECs. Biochem. Biophys. Res. Commun., 2008, 369, 718-724.
65. Shrikhande, G.; Khaodhiar, L.; Scali, S.; Lima, C.; Hubbard, M.; Dudley, K.; Ganda, O.; Ferran, C.; Veves, A. Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation. J. Vasc. Surg., 2006, 43, 760-770.
66. Koh, S.H.; Chang, D.I.; Kim, H.T.; Kim, J.; Kim, M.H.; Kim, K.S.; Bae, I.; Kim, H.; Kim, D.W.; Kim, S.H. Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model. Toxicology, 2005, 214, 131-139.
67. Koh, S.H.; Park, Y.; Song, C.W.; Kim, J.G.; Kim, K.; Kim, J.; Kim, M.H.; Lee, S.R.; Kim, D.W.; Yu, H.J.; Chang, D.I.; Hwang, S.J.; Kim, S.H. The effect of PARP inhibitor on ischaemic cell death, its related inflammation and survival signals. Eur. J. Neurosci., 2004, 20, 1461-1472.
68. Zhang, Y.; Rosenberg, P.A. Caspase-1 and poly (ADP-ribose) polymerase inhibitors may protect against peroxynitrite-induced neurotoxicity independent of their enzyme inhibitor activity. Eur. J. Neurosci., 2004, 20, 1727-1736.
69. Kamanaka, Y.; Kondo, K.; Ikeda, Y.; Kamoshima, W.; Kitajima, T.; Suzuki, Y.; Nakamura, Y.; Umemura, K. Neuroprotective effects of ONO-1924H, an inhibitor of poly ADP-ribose polymerase (PARP), on cytotoxicity of PC12 cells and ischemic cerebral damage. Life Sci., 2004, 76, 151-162.
70. Kendirci, M.; Zsengeller, Z.; Bivalacqua, T.J.; Gur, S.; Usta, M.F.; Chen, M.; Szabo, C.; Hellstrom, W.J. Poly(Adenosine diphosphate-ribose) polymerase inhibition preserves erectile function in rats after cavernous nerve injury. J. Urol., 2005, 174, 2054-2059.
71. Nakajima, H.; Kakui, N.; Ohkuma, K.; Ishikawa, M.; Hasegawa, T. A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. J. Pharmacol. Exp. Ther., 2005, 312, 472-481.
72. Kaundal, R.K.; Shah, K.K.; Sharma, S.S. Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation. Life Sci., 2006, 79, 2293-2302.
73. Goebel, D.J.; Winkler, B.S. Blockade of PARP activity attenuates poly(ADP-ribosyl)ation but offers only partial neuroprotection against NMDA-induced cell death in the rat retina. J. Neurochem., 2006, 98, 1732-1745.
74. Yap, E.; Tan, W.L.; Ng, I.; Ng, Y.K. Combinatorial-approached neuroprotection using pan-caspase inhibitor and poly (ADP-ribose) polymerase (PARP) inhibitor following experimental stroke in rats; is there additional benefit? Brain Res., 2008, 1195, 130-138.
75. Czapski, G.A.; Cakala, M.; Gajkowska, B.; Strosznajder, J.B. Poly(ADP-ribose) polymerase-1 inhibition protects the brain against systemic inflammation. Neurochem. Int., 2006, 49, 751-755.
76. Mota, R.A.; Hernandez-Espinosa, D.; Galbis-Martinez, L.; Ordonez, A.; Minano, A.; Parrilla, P.; Vicente, V.; Corral, J.; Yelamos, J. Poly(ADP-ribose) polymerase-1 inhibition increases expression of heat shock proteins and attenuates heat stroke-induced liver injury. Crit. Care Med., 2008, 36, 526-534.
77. Kofler, J.; Otsuka, T.; Zhang, Z.; Noppens, R.; Grafe, M.R.; Koh, D.W.; Dawson, V.L.; de Murcia, J.M.; Hurn, P.D.; Traystman, R.J. Differential effect of PARP-2 deletion on brain injury after focal and global cerebral ischemia. J. Cereb. Blood Flow Metab., 2006, 26, 135-141.
78. Diaz-Hernandez, J.I.; Moncada, S.; Bolanos, J.P.; Almeida, A. Poly(ADP-ribose) polymerase-1 protects neurons against apoptosis induced by oxidative stress. Cell Death Differ., 2007, 14, 1211-1221.
79. Alano, C.C.; Kauppinen, T.M.; Valls, A.V.; Swanson, R.A. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc. Natl. Acad. Sci. USA, 2006, 103, 9685-9690.
80. Palfi, A.; Toth, A.; Hanto, K.; Deres, P.; Szabados, E.; Szereday, Z.; Kulcsar, G.; Kalai, T.; Hideg, K.; Gallyas, F., Jr.; Sumegi, B.; Toth, K.; Halmosi, R. PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway. J. Mol. Cell Cardiol., 2006, 41, 149-159.
81. Benko, R.; Pacher, P.; Vaslin, A.; Kollai, M.; Szabo, C. Restoration of the endothelial function in the aortic rings of apolipoprotein E deficient mice by pharmacological inhibition of the nuclear enzyme poly(ADP-ribose) polymerase. Life Sci., 2004, 75, 1255-1261.
82. Szabo, G.; Soos, P.; Mandera, S.; Heger, U.; Flechtenmacher, C.; Bahrle, S.; Seres, L.; Cziraki, A.; Gries, A.; Zsengeller, Z.; Vahl, C.F.; Hagl, S.; Szabo, C. INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. Shock, 2004, 21, 426-432.
83. Hauser, B.; Groger, M.; Ehrmann, U.; Albicini, M.; Bruckner, U.B.; Schelzig, H.; Venkatesh, B.; Li, H.; Szabo, C.; Speit, G.; Radermacher, P.; Kick, J. The parp-1 inhibitor ino-1001 facilitates hemodynamic stabilization without affecting DNA repair in porcine thoracic aortic cross-clamping-induced ischemia/reperfusion. Shock, 2006, 25, 633-640.
84. Toth, O.; Szabo, C.; Kecskes, M.; Poto, L.; Nagy, A.; Losonczy, H. In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters. Life Sci., 2006, 79, 317-323.
85. Di Paola, R.; Mazzon, E.; Muia, C.; Terrana, D.; Greco, S.; Britti, D.; Santori, D.; Oteri, G.; Cordasco, G.; Cuzzocrea, S. 5-Aminoisoquinolin-1(2H)-one, a water-soluble poly (ADP-ribose) polymerase (PARP) inhibitor reduces the evolution of experimental periodontitis in rats. J. Clin. Periodontol., 2007, 34, 95-102.
86. Di Paola, R.; Mazzon, E.; Xu, W.; Genovese, T.; Ferrraris, D.; Muia, C.; Crisafulli, C.; Zhang, J.; Cuzzocrea, S. Treatment with PARP-1 inhibitors, GPI 15427 or GPI 16539, ameliorates intestinal damage in rat models of colitis and shock. Eur. J. Pharmacol., 2005, 527, 163-171.
87. Mazzon, E.; Genovese, T.; Di Paola, R.; Muia, C.; Crisafulli, C.; Malleo, G.; Esposito, E.; Meli, R.; Sessa, E.; Cuzzocrea, S. Effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase, in a mouse model of acute pancreatitis induced by cerulein. Eur. J. Pharmacol., 2006, 549, 149-156.
88. Zheng, J.; Devalaraja-Narashimha, K.; Singaravelu, K.; Padanilam, B.J. Poly(ADP-ribose) polymerase-1 gene ablation protects mice from ischemic renal injury. Am. J. Physiol. Renal. Physiol., 2005, 288, F387-398.
89. Suzuki, Y.; Masini, E.; Mazzocca, C.; Cuzzocrea, S.; Ciampa, A.; Suzuki, H.; Bani, D. Inhibition of poly(ADP-ribose) polymerase prevents allergen-induced asthma-like reaction in sensitized Guinea pigs. J. Pharmacol. Exp. Ther., 2004, 311, 1241-1248.
90. Miwa, M.; Masutani, M. PolyADP-ribosylation and cancer. Cancer Sci., 2007, 98, 1528-1535.
91. Pan, Q.C.; Guo, H.Y. The potentiation of the antitumor activity but not toxicity of bleomycin by 3-aminobenzamide. J. Antibiot., 1989, 42, 1860-1868.
92. Petrou, C.; Mourelatos, D.; Mioglou, E.; Dozi-Vassiliades, J.; Catsoulacos, P. Effects of alkylating antineoplastics alone or in combination with 3-aminobenzamide on genotoxicity, antitumor activity, and NAD levels in human lymphocytes in vitro and on Ehrlich ascites tumor cells in vivo. Teratog. Carcinog. Mutagen., 1990, 10, 321-331.
93. Jacob, D.A.; Bahra, M.; Langrehr, J.M.; Boas-Knoop, S.; Stefaniak, R.; Davis, J.; Schumacher, G.; Lippert, S.; Neumann, U.P. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. J. Gastroenterol. Hepatol., 2007, 22, 738-748.
94. Schlicker, A.; Peschke, P.; Bürkle, A.; Hahn, E.W.; Kim, J.H. 4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer. Int. J. Radiat. Biol., 1999, 75, 91-100.
95. Munoz-Gamez, J.A.; Martin-Oliva, D.; Aguilar-Quesada, R.; Canuelo, A.; Nunez, M.I.; Valenzuela, M.T.; Ruiz de Almodovar, J.M.; De Murcia, G.; Oliver, F.J. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem. J., 2005, 386, 119-125.
96. Calabrese, C.R.; Almassy, R.; Barton, S.; Batey, M.A.; Calvert, A.H.; Canan-Koch, S.; Durkacz, B.W.; Hostomsky, Z.; Kumpf, R.A.; Kyle, S.; Li, J.; Maegley, K.; Newell, D.R.; Notarianni, E.; Stratford, I.J.; Skalitzky, D.; Thomas, H.D.; Wang, L.Z.; Webber, S.E.; Williams, K.J.; Curtin, N.J. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst., 2004, 96, 56-67.
97. Brock, W.A.; Milas, L.; Bergh, S.; Lo, R.; Szabo, C.; Mason, K.A. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett., 2004, 205, 155-160.
98. Mason, K.A.; Valdecanas, D.; Hunter, N.R.; Milas, L. INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Invest. New Drugs, 2008, 26, 1-5.
99. Tentori, L.; Leonetti, C.; Scarsella, M.; Muzi, A.; Mazzon, E.; Vergati, M.; Forini, O.; Lapidus, R.; Xu, W.; Dorio, A.S.; Zhang, J.; Cuzzocrea, S.; Graziani, G. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/ temozolomide efficacy against colon carcinoma. FASEB J., 2006, 20, 1709-1711.
100. Albert, J.M.; Cao, C.; Kim, K.W.; Willey, C.D.; Geng, L.; Xiao, D.; Wang, H.; Sandler, A.; Johnson, D.H.; Colevas, A.D.; Low, J.; Rothenberg, M.L.; Lu, B. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin. Cancer Res., 2007, 13, 3033-3042.
101. Donawho, C.K.; Luo, Y.; Luo, Y.; Penning, T.D.; Bauch, J.L.; Bouska, J.J.; Bontcheva-Diaz, V.D.; Cox, B.F.; DeWeese, T.L.; Dillehay, L.E.; Ferguson, D.C.; Ghoreishi-Haack, N.S.; Grimm, D.R.; Guan, R.; Han, E.K.; Holley-Shanks, R.R.; Hristov, B.; Idler, K.B.; Jarvis, K.; Johnson, E.F.; Kleinberg, L.R.; Klinghofer, V.; Lasko, L.M.; Liu, X.; Marsh, K.C.; McGonigal, T.P.; Meulbroek, J.A.; Olson, A.M.; Palma, J.P.; Rodriguez, L.E.; Shi, Y.; Stavropoulos, J.A.; Tsurutani, A.C.; Zhu, G.D.; Rosenberg, S.H.; Giranda, V.L.; Frost, D.J. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res., 2007, 13, 2728-2737.
102. Blackburn, E.H.; Greider, C.W.; Szostak, J.W. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat. Med., 2006, 12, 1133-1138.
103. Harley, C.B.; Futcher, A.B.; Greider, C.W. Telomeres shorten during ageing of human fibroblasts. Nature, 1990, 345, 458-60.
104. Hiyama, E.; Hiyama, K. Telomerase as tumor marker. Cancer Lett., 2003, 194, 221-233.
105. Nugent, C.I.; Lundblad, V. The telomerase reverse transcriptase: components and regulation. Genes Dev., 1998, 12, 1073-1085.
106. de Lange, T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev., 2005, 19, 2100-2110.
107. Hsiao, S.J.; Smith, S. Tankyrase function at telomeres, spindle poles, and beyond. Biochimie, 2008, 90, 83-92.
108. Seimiya, H. The telomeric PARP, tankyrases, as targets for cancer therapy. Br. J. Cancer, 2006, 94, 341-345.
109. Beneke, S.; Cohausz, O.; Malanga, M.; Boukamp, P.; Althaus, F.; Burkle, A. Rapid regulation of telomere length is mediated by poly(ADP-ribose) polymerase-1. Nucleic Acids Res., 2008, 36, 6309-6317.
110. Meyer, R.G.; Meyer-Ficca, M.L.; Jacobson, E.L.; Jacobson, M.K. Human poly(ADP-ribose) glycohydrolase (PARG) gene and the common promoter sequence it shares with inner mitochondrial membrane translocase 23 (TIM23). Gene, 2003, 314, 181-190.
111. Meyer-Ficca, M.L.; Meyer, R.G.; Coyle, D.L.; Jacobson, E.L.; Jacobson, M.K. Human poly(ADP-ribose) glycohydrolase is expressed in alternative splice variants yielding isoforms that localize to different cell compartments. Exp. Cell Res., 2004, 297, 521-532.
112. Meyer, R.G.; Meyer-Ficca, M.L.; Whatcott, C.J.; Jacobson, E.L.; Jacobson, M.K. Two small enzyme isoforms mediate mammalian mitochondrial poly(ADP-ribose) glycohydrolase (PARG) activity. Exp. Cell Res., 2007, 313, 2920-2936.
113. Oka, S.; Kato, J.; Moss, J. Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase. J. Biol. Chem., 2006, 281, 705-713.
114. Koh, D.W.; Lawler, A.M.; Poitras, M.F.; Sasaki, M.; Wattler, S.; Nehls, M.C.; Stoger, T.; Poirier, G.G.; Dawson, V.L.; Dawson, T.M. Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proc. Natl. Acad. Sci. USA, 2004, 101, 17699-17704.
115. Cortes, U.; Tong, W.M.; Coyle, D.L.; Meyer-Ficca, M.L.; Meyer, R.G.; Petrilli, V.; Herceg, Z.; Jacobson, E.L.; Jacobson, M.K.; Wang, Z.Q. Depletion of the 110-kilodalton isoform of poly(ADP-ribose) glycohydrolase increases sensitivity to genotoxic and endotoxic stress in mice. Mol. Cell Biol., 2004, 24, 7163-7178.
116. Hanai, S.; Kanai, M.; Ohashi, S.; Okamoto, K.; Yamada, M.; Takahashi, H.; Miwa, M. Loss of poly(ADP-ribose) glycohydrolase causes progressive neurodegeneration in Drosophila melanogaster. Proc. Natl. Acad. Sci. USA, 2004, 101, 82-86.
117. Slama, J.T.; Aboul-Ela, N.; Jacobson, M.K. Mechanism of inhibition of poly(ADP-ribose) glycohydrolase by adenosine diphosphate (hydroxymethyl)pyrrolidinediol. J. Med. Chem., 1995, 38, 4332-4336.
118. Koh, D.W.; Patel, C.N.; Ramsinghani, S.; Slama, J.T.; Oliveira, M.A.; Jacobson, M.K. Identification of an inhibitor binding site of poly(ADP-ribose) glycohydrolase. Biochemistry, 2003, 42, 4855-4863.
119. Tsai, Y.J.; Aoki, T.; Maruta, H.; Abe, H.; Sakagami, H.; Hatano, T.; Okuda, T.; Tanuma, S. Mouse mammary tumor virus gene expression is suppressed by oligomeric ellagitannins, novel inhibitors of poly(ADP-ribose) glycohydrolase. J. Biol. Chem., 1992, 267, 14436-14442.
120. Falsig, J.; Christiansen, S.H.; Feuerhahn, S.; Burkle, A.; Oei, S.L.; Keil, C.; Leist, M. Poly(ADP-ribose) glycohydrolase as a target for neuroprotective intervention: assessment of currently available pharmacological tools. Eur. J. Pharmacol., 2004, 497, 7-16.
121. Tentori, L.; Leonetti, C.; Scarsella, M.; Muzi, A.; Vergati, M.; Forini, O.; Lacal, P.M.; Ruffini, F.; Gold, B.; Li, W.; Zhang, J.; Graziani, G. Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. Eur. J. Cancer, 2005, 41, 2948-2957.
122. Cuzzocrea, S.; Mazzon, E.; Genovese, T.; Crisafulli, C.; Min, W.K.; Di Paola, R.; Muia, C.; Li, J.H.; Malleo, G.; Xu, W.; Massuda, E.; Esposito, E.; Zhang, J.; Wang, Z.Q. Role of poly(ADP-ribose) glycohydrolase in the development of inflammatory bowel disease in mice. Free Radic. Biol. Med., 2007, 42, 90-105.
123. Khan, J.A.; Tao, X.; Tong, L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat. Struct. Mol. Biol., 2006, 13, 582-588.
124. Hufton, S.E.; Moerkerk, P.T.; Brandwijk, R.; de Bruine, A.P.; Arends, J.W.; Hoogenboom, H.R. A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett., 1999, 463, 77-82.
125. Van Beijnum, J.R.; Moerkerk, P.T.; Gerbers, A.J.; De Bruine, A.P.; Arends, J.W.; Hoogenboom, H.R.; Hufton, S.E. Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int. J. Cancer, 2002, 101, 118-127.
126. Hasmann, M.; Schemainda, I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res., 2003, 63, 7436-7442.
127. Muruganandham, M.; Alfieri, A.A.; Matei, C.; Chen, Y.; Sukenick, G.; Schemainda, I.; Hasmann, M.; Saltz, L.B.; Koutcher, J.A. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin. Cancer Res., 2005, 11, 3503-3513.
128. Wosikowski, K.; Mattern, K.; Schemainda, I.; Hasmann, M.; Rattel, B.; Loser, R. WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. Cancer Res., 2002, 62, 1057-1062.
129. Galli, U.; Ercolano, E.; Carraro, L.; Blasi Roman, C.R.; Sorba, G.; Canonico, P.L.; Genazzani, A.A.; Tron, G.C.; Billington, R.A. Synthesis and Biological Evaluation of Isosteric Analogues of FK866, an Inhibitor of NAD Salvage. Chem. Med. Chem., 2008, 3 (5), 771-779.
130. Scovassi, A.I. The poly(ADP-ribosylation) story: a long route from Cinderella to Princess. Riv. Biol., 2007, 100, 351-360.